5-羟基吡嗪-2-羧酸 | 34604-60-9

• 物质功能分类: 医药中间体 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-羟基吡嗪-2-羧酸
• 中文别名: 5-羟基-2-吡嗪羧基酸；-羟基吡嗪-2-羧酸；5-羟基-2-甲酸吡嗪；5-羟基-2-羧酸吡嗪；5-羟基吡嗪-2-甲酸；5-羟基-2-吡嗪羧酸
• 英文名称: 5-hydroxypyrazinoic acid
• 英文别名: 5-hydroxypyrazine-2-carboxylic acid；5-hydroxy-2-pyrazine carboxylic acid；6-oxo-1H-pyrazine-3-carboxylic acid
• CAS: 34604-60-9
• 化学式: C₅H₄N₂O₃
• mdl: MFCD00190599
• 分子量: 140.098
• InChiKey: CGQFCIHUUCMACC-UHFFFAOYSA-N

物化性质

• 熔点：
  >295°C (dec.)
• 密度：
  1.63±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（轻微、加热）、甲醇（非常轻微、加热）
• LogP：
  -1.820 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Hydroxypyrazine-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Hydroxypyrazine-2-carboxylic acid
CAS number: 34604-60-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H4N2O3
Molecular weight: 140.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性方面，5-羟基吡唑-2-羧酸是抗肺结核药物吡嗪酰胺（PZA）的代谢产物。

反应信息

• 作为反应物：
  描述：

  5-羟基吡嗪-2-羧酸 在 ammonium hydroxide 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 3.5h， 生成 5-氨基吡嗪-2-羧酰胺
  参考文献：
  名称：

  Alkylamino derivatives of pyrazinamide: Synthesis and antimycobacterial evaluation

  摘要：

  A series of pyrazinamide derivatives with alkylamino substitution was designed, synthesized and tested for their ability to inhibit the growth of selected mycobacterial, bacterial and fungal strains. The target structures were prepared from the corresponding 5-chloro (1) or 6-chloropyrazine-2-carboxamide (2) by nucleophilic substitution of chlorine by various non-aromatic amines (alkylamines). To determine the influence of alkyl substitution, corresponding amino derivatives (1a, 2a) and compounds with phenylalkylamino substitution were prepared. Some of the compounds exerted antimycobacterial activity against Mycobacterium tuberculosis H37Rv significantly better than standard pyrazinamide and corresponding starting compounds (1 and 2). Basic structure-activity relationships are presented. Only weak antibacterial and no antifungal activity was detected. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.054
• 作为产物：
  描述：

  5-氯吡嗪-2-羧酸 在 sodium hydroxide 作用下， 反应 1.0h， 以100%的产率得到5-羟基吡嗪-2-羧酸
  参考文献：
  名称：

  Sato, Nobuhiro; Arai, Shinji, Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 407 - 408

  摘要：

  DOI：

文献信息

• [EN] ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES D'ARYLMÉTHYLÈNE UTILISÉS EN TANT QUE BLOQUEURS DES CANAUX POTASSIQUES KV1.3 DE TYPE SHAKER
  申请人：DE SHAW RES LLC

  公开号：WO2021071806A1

  公开（公告）日：2021-04-15

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

  描述了化合物的公式（I）或其药学上可接受的盐，其中取代基如本文所定义。还描述了包含相同化合物的药物组合物以及使用该药物的方法。
• [EN] N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS<br/>[FR] DÉRIVÉS DE N-(HÉTÉROCYCLYL ET HÉTÉROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE SERVANT D'AGONISTES DE SSTR4
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2021202775A1

  公开（公告）日：2021-10-07

  Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein n, R1, R4, R5, R6, R7, R8, R9, R10, R11, R14, X2, X3 and X12 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

  披露了公式（1）的化合物，以及其中n、R1、R4、R5、R6、R7、R8、R9、R10、R11、R14、X2、X3和X12在说明书中定义的药用可接受盐。本公开还涉及用于制备公式（1）化合物的材料和方法，含有它们的药物组合物，以及它们用于治疗与SSTR4相关的疾病、障碍和状况。
• [EN] 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS<br/>[FR] DÉRIVÉS DE 5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZINE COMME MODULATEURS DE P2X7
  申请人：GLAXO GROUP LTD

  公开号：WO2010125102A1

  公开（公告）日：2010-11-04

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6 R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.

  本发明提供了一种式(I)化合物或其药学上可接受的盐，其中A为氢、C1-4烷基、C3-6环烷基、C1-3烷氧基、C1-3烷氧基C1-4烷基、C1-2氟烷基、卤素、NR6 R7、任选取代的杂芳基(Het)或任选取代的苯基，且R1、R2、R3、R4、R5、R6和R7如说明书中所定义。这些化合物或盐被认为能够调节P2X7受体功能，并能拮抗ATP在P2X7受体上的作用。本发明还提供了该化合物或盐在治疗或预防例如炎症性疼痛、神经性疼痛、内脏疼痛、类风湿性关节炎、骨关节炎或神经退行性疾病中的用途。
• Synthesis, Antimycobacterial Activity and In Vitro Cytotoxicity of 5-Chloro-N-phenylpyrazine-2-carboxamides
  作者：Jan Zitko、Barbora Servusová、Pavla Paterová、Jana Mandíková、Vladimír Kubíček、Radim Kučera、Veronika Hrabcová、Jiří Kuneš、Ondřej Soukup、Martin Doležal

  DOI：10.3390/molecules181214807

  日期：——

  tuberculosis H37Rv, M. kansasii and two strains of M. avium. Most of the compounds exerted activity against M. tuberculosis H37Rv in the range of MIC = 1.56–6.25 µg/mL and only three derivatives were inactive. The phenyl part of the molecule tolerated many different substituents while maintaining the activity. In vitro cytotoxicity was decreased in compounds with hydroxyl substituents, preferably combined

  5-氯吡嗪酰胺 (5-Cl-PZA) 是分枝杆菌脂肪酸合酶 I 的抑制剂，在体外具有广谱抗分枝杆菌活性。一些在吡嗪和苯基核上具有不同取代基的 N-苯基吡嗪-2-甲酰胺对结核分枝杆菌具有显着的体外活性。为了测试结合 5-Cl-PZA 和苯胺基序的结构的活性，合成了一系列三十个 5-氯-N-苯基吡嗪-2-甲酰胺，在苯环上具有各种取代基 R，并针对结核分枝杆菌 H37Rv 进行筛选， M. kansasii 和两个 M. avium 菌株。大多数化合物对结核分枝杆菌 H37Rv 的活性范围为 MIC = 1.56–6.25 µg/mL，只有三种衍生物无活性。分子的苯基部分耐受许多不同的取代基，同时保持活性。具有羟基取代基的化合物的体外细胞毒性降低，优选与其他亲水性取代基组合。5-氯-N-(5-氯-2-羟基苯基)吡嗪-2-甲酰胺 (21) 抑制所有测试菌株（MIC = 1.56 µg/mL 结核分枝杆菌；12
• [EN] NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY<br/>[FR] NITROIMIDAZOOXAZINES ET LEURS UTILISATIONS EN THÉRAPIE ANTITUBERCULEUSE
  申请人：GLOBAL ALLIANCE FOR TB DRUG DEV

  公开号：WO2011014774A1

  公开（公告）日：2011-02-03

  The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

  本发明涉及新型硝基咪唑噁啉类化合物，其制备方法，以及它们作为治疗结核分枝杆菌和其他微生物感染的药物的用途，可以单独使用或与其他抗感染治疗方法结合使用。